北京大学学报(医学版) ›› 2024, Vol. 56 ›› Issue (1): 51-56. doi: 10.19723/j.issn.1671-167X.2024.01.009
Ying ZHOU,Ning ZHAO,Hongyuan HUANG,Qingxiang LI,Chuanbin GUO,Yuxing GUO*()
摘要:
目的: 探究双层软组织缝合封闭技术在单纯应用抗骨吸收药物引起的发生在下颌骨的中早期药物相关性颌骨骨坏死(medication-related osteonecrosis of the jaw, MRONJ)患者手术治疗中的临床应用效果。方法: 选择2021年10月至2022年9月于北京大学口腔医院四病区经手术治疗的中早期下颌骨MRONJ患者的病历资料进行回顾性分析,收集患者术前基线临床资料,包括原发疾病、伴发疾病、用药方案(药物种类、用药时长)、MRONJ分期、临床症状、影像学表现等,所有患者在手术中行下颌骨边缘切除术去除坏死骨,运用双层软组织缝合封闭技术关闭伤口,术后定期复查随访,评价双层软组织缝合封闭技术的治疗效果及并发症,并对患者进行疼痛评分和功能状态评价。结果: 研究共纳入13例患者(女12例,男1例),年龄(66.69±13.14)岁。原发疾病包括骨质疏松7例,肺癌2例,乳腺癌3例,前列腺癌1例;2例伴发糖尿病,2例伴发心血管疾病,1例伴发干燥综合征。9例患者静脉注射唑来膦酸,平均用药时间(37.7±20.0)个月,7例患者同时服用了来曲唑片等其他药物;3例患者应用地舒单抗注射液,平均用药时间(10.3±11.9)个月;5例患者服用阿仑膦酸钠片,平均用药时间(55.20±27.20)个月,2例患者不同程度地服用醋酸泼尼松片或阿卡波糖片。MRONJ 1期4例,2期9例。13例患者均采用双层软组织缝合封闭技术关闭伤口,术后平均随访11.9个月(9~17个月),13例患者皆治愈,无溢脓等并发症发生。患者术前Karnofsky功能状态评分量表(Karnofsky performance status, KPS)评分为(68.46±14.05)分,术后评分为(82.31±15.36)分,差异有统计学意义(P < 0.05)。患者术前疼痛评估视觉模拟评分量表(visual analogue scale,VAS)评分为(5.77±0.73)分,术后评分为(0.38±0.51)分,差异有统计学意义(P < 0.001)。结论: 双层软组织缝合封闭技术在中早期单纯使用抗骨吸收类药物的下颌骨MRONJ患者中可以取得良好的临床治疗效果,可为用药情况更加复杂的MRONJ患者提供临床治疗思路。
中图分类号:
1 |
Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61 (9): 1115- 1117.
doi: 10.1016/S0278-2391(03)00720-1 |
2 |
Ruggiero SL , Dodson TB . American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72 (10): 1938- 1956.
doi: 10.1016/j.joms.2014.04.031 |
3 |
郭玉兴, 王佃灿, 王洋, 等. 二膦酸盐药物治疗乳腺癌骨转移发生颌骨坏死的临床特点[J]. 北京大学学报(医学版), 2016, 48 (1): 80- 83.
doi: 10.3969/j.issn.1671-167X.2016.01.014 |
4 |
Ruggiero SL , Dodson TB , Aghaloo T , et al. American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws: 2022 update[J]. J Oral Maxillofac Surg, 2022, 80 (5): 920- 943.
doi: 10.1016/j.joms.2022.02.008 |
5 |
Yarom N , Shapiro CL , Peterson DE , et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37 (25): 2270- 2290.
doi: 10.1200/JCO.19.01186 |
6 |
Carlson ER . Management of antiresorptive osteonecrosis of the jaws with primary surgical resection[J]. J Oral Maxillofac Surg, 2014, 72 (4): 655- 657.
doi: 10.1016/j.joms.2013.12.007 |
7 |
Abu-ld MH , Warnke PH , Gottschalk J , et al. "Bis-phossy jaws"-high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2008, 36 (2): 95- 103.
doi: 10.1016/j.jcms.2007.06.008 |
8 |
Wilde F , Heufelder M , Winter K , et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 111 (2): 153- 163.
doi: 10.1016/j.tripleo.2010.04.015 |
9 |
Hayashida S , Soutome S , Yanamoto S , et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis[J]. J Bone Miner Res, 2017, 32 (10): 2022- 2029.
doi: 10.1002/jbmr.3191 |
10 |
Williamson RA . Surgical management of bisphosphonate induced osteonecrosis of the jaws[J]. Int J Oral Maxillofac Surg, 2010, 39 (3): 251- 255.
doi: 10.1016/j.ijom.2009.11.014 |
11 |
Lopes RN , Rabelo GD , Rocha AC , et al. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: Six-year experience of a single institution[J]. J Oral Maxillofac Surg, 2015, 73 (7): 1288- 1295.
doi: 10.1016/j.joms.2015.01.008 |
12 | 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21 (4): 313- 325. |
13 |
Altay MA , Radu A , Pack SE , et al. Medication-related osteonecrosis of the jaw: An institution' s experience[J]. Cranio, 2020, 38 (5): 333- 341.
doi: 10.1080/08869634.2018.1528711 |
14 |
安金刚, 吕晓鸣, 贾宽宽, 等. 下颌下腺转位在下颌骨3期药物相关性颌骨坏死手术中的应用[J]. 中华口腔医学杂志, 2021, 56 (5): 441- 446.
doi: 10.3760/cma.j.cn112144-20210203-00058 |
15 |
Caldroney S , Ghazali N , Dyalram D , et al. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw[J]. Int J Oral Maxillofac Surg, 2017, 46 (7): 871- 876.
doi: 10.1016/j.ijom.2017.01.023 |
16 |
Klingelhöffer C , Zeman F , Meier J , et al. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2016, 44 (10): 1694- 1699.
doi: 10.1016/j.jcms.2016.08.001 |
17 |
Mücke T , Koerdt S , Jung M , et al. The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2016, 44 (4): 369- 373.
doi: 10.1016/j.jcms.2015.12.017 |
18 |
Lemound J , Muecke T , Zeller AN , et al. Nasolabial flap improves healing in medication-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2018, 76 (4): 877- 885.
doi: 10.1016/j.joms.2017.09.021 |
[1] | 杨榕,李庆祥,毛驰,彭歆,王洋,郭玉兴,郭传瑸. 多模态影像融合技术与颅底-颞下区肿瘤的诊断和治疗[J]. 北京大学学报(医学版), 2019, 51(1): 53-58. |
[2] | 孙宇, 刘忠军, 党耕町. 颈椎病外科治疗的回顾[J]. 北京大学学报(医学版), 2002, 34(5): 627-629. |
|